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1. Introduction 
Neuroblastoma X glioma hybrid cells express many 
properties characteristic of neurons. Among these is 
their response to various neurohormones. Prostaglandin 
El (PGE,) increases the intracellular level of adenosine 
3’,5’-cyclic monophosphate (cyclic AMP)‘in the hybrid 
cells. This increase is inhibited by opioids, cholinergic 
and adrenergic agonists (for review see ref. [l-3] ). 
Here we report that also the tetradecapeptide somato- 
statin (somatotropin release inhibitory factor, SRIF) 
[4] blocks the raise in the level of cyclic AMP caused by 
PGE1. First discovered in hypothalamus [S], SRIF 
occurs also in other parts of the brain [6], in the 
pancreas [7], stomach [7,8] and the gut [9]. It 
inhibits the release of somatotropin [5] and other 
hormones such as glucagon, insulin and gastrin [ 10,l l] . 
Also the release of somatotropin evoked by morphine 
[ 12,131 is inhibited by SRIF [ 131. Therefore it was 
hypothesized that SRIF might act as an antagonist of 
morphine by occupying the same receptor. Experi- 
mental support for this view was given [ 141. On the 
other hand it has been reported that SRIF applied 
cerebroventricularly causes analgesia like morphine 
does [15]. 
Evidence is presented here that in the hybrid cells 
the specific opioid antagonist naloxone does not 
inhibit the action of SRIF and that SRIF does not 
block the specific binding of [3H]naloxone to the 
opioid receptors of the hybird cells. It is concluded 
that the receptors for opioids and SRIF are different 
entities. 
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2. Materials and methods 
Somatostatin preparations from the following 
sources were used: UCB Bioproducts, Brussels; Beckman 
Instruments, Geneva; and Kabi, Stockholm (gift from 
Dr A. WahlstrGm). Leucine-enkephalin was a gift 
Drs L. Moroder and E. Wiinsch,Martinsried; PGElfrom 
Dr J. Pike, Upjohn Co., Kalamazoo, Michigan; etorphine 
from A. Herz, Munich; naloxone.HCI and RO20-1724 
from Hoffmann-LaRoche, Grenzach, FRG. [3H]Naloxone 
(20.0 Ci/mmol) was from New England Nuclear. 
Plating of the cells on to plastic Petri dishes and 
growth have been described previously [ 161. For 
experimental incubation in dishes 85 mm in diameter 
the growth medium was removed and the cells were 
washed with 5 ml incubation medium [ 171. Subse- 
quently the cells were incubated with 5 ml incubation 
medium and the various additions at 37°C for 10 min. 
After the incubation the cellular concentration of cyclic 
AMP was determined [ 161. 
For measuring binding of [3H]naloxone to hybrid 
cells, 5.6-6.3 X lo6 viable hybrid cells (viability 70%, 
exclusion of nigrosin) per plastic plate (150 mm in 
diameter) were harvested by incubation (4”C, 10 min) 
with medium Dl that had been adjusted [ 181 to 330 
mOsmo1 with glucose and sucrose. After centrifugation 
the cells were resuspended in incubation buffer (50 
mM Na-phosphate, 50 mM NaCl, 20 mM glucose, 100 
mM sucrose, 0.8 MgC12, pH 7.4). For the determination 
of specific plus unspecific binding, cells containing 1 
mg protein were incubated (37”C, 10 min) with 4.5 
nM [3H]naloxone (20.0 Ci/mmol) in incubation buffer. 
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For the determination of unspecific binding, 0.1 mM 
unlabelled naloxone was included in a parallel incu- 
bation. The difference of the data obtained in the two 
incubations is the specific binding. After the incubation, 
the mixtures were filtered by suction through Whatman 
GF/B filters (2.4 cm in diameter) and washed with 
10 ml ice-cold incubation buffer. Before counting 
radioactivity, the filters were incubated for 6 h in 
scintillation vials containing 10 ml Rotiszint (C. Roth, 
Karlsruhe, FRG). 
3. Results 
In the hybrid cells the strong elevation in the level 
of cyclic AMP caused by PGEi is inhibited by SRIF 
(fig.1, curve c). Half-maximal inhibition (ZCse) occurs 
already at a concentration of 1 nM. As reported 
previously [ 16,191, also the opioid peptide leucine- 
enkephalin [20] inhibits the effect of PGE,. The 
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influence of the opioid peptide is not blocked by SRIF 
(tig.1, curves a and b). Rather, SRIF appears to some- 
what enhance the effect of enkephalin. Thus, these 
results do not support the view [ 141 that SRIF is a 
partial opioid antagonist. SRIF appears to act by 
inhibiting the adenylate cyclase activity of the hybrid 
cells. During an incubation (10 min) with 0.5 mM 
phosphodiesterase inhibitor R020-1724 (ref. [21]) the 
intracellular level of cyclic AMPincreased from 5-535 
+ 70 pmol/mg protein. If 0.1 FM SRIF was also 
present, a reduced value 290 + 1 pmol/mg protein was 
obtained. The result indicates that SRIF can even 
lower the basal rate of formation of cyclic AMP. 
Neither phentolamine, a blocker of a-adrenergic 
receptors, nor atropin, a blocker of muscarinic cholin- 
ergic receptors, prevent the effect of SRIF (data not 
shown). This eliminates the possibility that SRIF acts 
by occupying one of these receptors also present on 
the hybrid cells (2,3]. If SRIF would act via opioid 
receptors, its action should be blocked by the specific 
opioid antagonist naloxone. Although naloxone reverses 
the inhibitory effect of leucine-enkephalin (fig. 2, 
curve b), it does not suppress that of SRIF (fig.2, curve a). 
These results are corroborated by studies of the 
specific binding of [3H]naloxone to the opioid receptors 
of intact hybrid cells. While the morphine congener 
etorphine competes effectively with labelled naloxone 
for the specific opioid binding sites (fig.3, curve a), 
SRIF is unable to do so (tig.3, curve b). The SRIF 
was still active at the end of the binding assay. This 
was demonstrated by the fact that it was still able to 
inhibit the increase in the level of cyclic AMP caused 
by PGEr (assay of the type shown in fig.1). 
Fig.1. SRJF inhibits the elevation by PGE, (0.3 PM) of the 
level of cyclic AMP in the neuroblastoma X glioma hybrid 
line 108CClS (curve c). It does not antagonize the block by 
10 nM (curve a) or 100 nM (curve b) leucine-enkephalin of 
such an elevation. 2.5 X lo6 viable cells/plate, 85 mm in 
diameter, 98% viability, passage number 17. Each value is the 
mean t S. D. of data obtained from three parallel incubations. 
Basal level of cyclic AMP in the absence of additions: 14 fi 1 
pmol/mg protein. The SRIF used here was a product of 
Beckman Instruments. Practically identical results were ob- 
tained with SRIF produced by Kabi or UCB Bioproducts. 
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Fig.2. Naloxone prevents the inhibition by leucine-enkephalin 
but not by SRIF of the PGE, -induced increase in the level of 
cyclic AMP. (Curve a) 0.3 PM PGE, + 0.1 PM SRIF; (Curve b) 
PGE, + 0.1 PM leucine-enkephalin; (Curve c) PGE, 1.8 X lo6 
viable 108CClS cells per plate, viability 90%, passage number 
21. Basal evel of cyclic AMP: 15 + 2 pmol/mg protein. 
Other details as in fig. 1. 
4. Discussion 
SRIF has previously been shown to prevent the 
increase in the level of cyclic AMP that was elicited 
when rat anterior pituitary was incubated with PGEr 
[22-261, thyroliberin [24] or a cyclic nucleotide 
phosphodiesterase inhibitor [27], when rat pancreatic 
islets were exposed to glucose [28] or when rat 
hepatocytes [29] or their membranes [30] were 
incubated with glucagon. In congruence with these 
findings is the observation that the inhibition by 
SRIF of acid secretion from gastric mucosa is overcome 
by the dibutyryl derivative of cyclic AMP [31]. The 
present work is in accord with these reports. It provides 
b 
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Fig.3. The morphine congener etorphine (curve a), but not 
SRIF (curve b), competes with [ ‘Hlnaloxone for the specific 
opioid binding sites of intact hybrid cells 108CC15. The data 
of curves a and b are mean values + S. D. of mean values 
(triplicates) from three and four independent experiments 
respectively. The SRIF was from UCB Bioproducts. 
5.6-6.3 X lo6 viable hybrid cells (viability 70%) per plastic 
plate 150 mm in diameter were harvested as described under 
Materials and methods. Range of passage numbers: 16-19. 
evidence that the neuroblastoma X glioma hybrid 
cells carry receptors for SRIF that are not identical 
with those for opioids or cholinergic or adrenergic 
agonists. Recently, it was reported that the release of 
noradrenaline from a human neuroblastoma line could 
be blocked by SRIF [32]. In analogy the hybrid cells 
may be used for studying the regulation of the release 
of acetylcholine, a neurotransmitter they synthesize 
(K. Kiirzinger, unpublished). Since the hybrid cells can 
be cultured in large quantities or be grown as tumors 
in mice [33], they may be a useful source for the 
isolation of the SRIF receptors. The absence of other 
cell types and the simplicity of the culture technique 
make the hybrid cells an attractive system for studying 
the mechanism of action of SRIF. 
The analogy in the short-term effects on the hybrid 
cells of SRIF, opioids, choline@ and adrenergic 
agonists suggests a common mechanism of action of the 
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complexes which these compounds form with their 
respective receptors. It is also expected that SRIF causes 
long-term effects similar to those of the three other 
classes of compounds. Such effects have been inter- 
preted as biochemical correlates of opiate tolerance, 
dependence and withdrawal phenomena [2,3]. 
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